Companies - Esperite

Price

 
Price
€ 0,51
Change
€ -0,02
Change %
-3,66%
Open
€ 0,52
High
€ 0,53
Low
€ 0,51
Volume
211.639

Profile

 
Profile
Esperite is the largest stem cell bank in Europe. The group specializes in isolating, collecting and preserving adult stem cells obtained from the blood of umbilical cords and umbilical tissue.
Industry
Biotechnology
Description
Companies in the biotechnology industry are performing research and development activities for the purpose of discovering new drugs and diagnostics. The turnover of these companies comes from sales of these products or the sale of licenses of drugs and diagnostic to other companies.

Key figures (2015)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
-0,719
Price to Earnings (3 years)
-0,977
Price to Earnings (5 years)
-0,836
Price to earnings growth
-
Price/cashflow
-1,161
Price/net cashflow
-0,043
Price/book value
0,333
Price to sales
0,184

Ratios for dividend

Dividend yield
-
Pay out
-

Valuation ratios

Market value/PE
0,333
Market value/turnover
0,184
Enterprise value/turnover
0,192

Return ratios

Return on private equity
-46,30%
Return on total equity
-14,67%
Profit margin
-25,65%

Risk ratios

Solvability
0,317
Solvability
1,464
Current ratio
0,985
Debt to Equity
2,157

Value invest ratios

Grahams Number
€ -1,92
Grahams Value
€ -2,43
Grahams Product
-0,239
Grahams Product (3 years)
-0,325

2015

 

Profit and loss

Net profit (x 1 mln)
€ -7,06
Turnover (x 1 mln)
€ 27,52
Cashflow(x 1 mln)
€ -4,37
Net cashflow(x 1 mln)
€ -119,00

Balance

Private equity (x 1 mln)
€ 15,25
Foreign equity (x 1 mln)
€ 32,89
Current assets (x 1 mln)
€ 13,59
Current liabilities (x 1 mln)
€ 13,80
Working capital (x 1 mln)
€ -0,21
Balance total (x 1 mln)
€ 48,14

Share

Outstanding shares (x 1 mln)
10,031
Price year-end
€ 2,35
Dividend per share
-
Earnings per share
€ -0,70
Cashflow per share
€ -0,44
Net cashflow per share
€ -11,86
Book value per share
€ 1,52
Stockmarket value (x 1 mln)
€ 23,57

History

 
Year
2015
2014
2013
2012
2011
Net profit (x 1 mln)
€ -7,06
€ -5,01
€ -3,51
€ -17,10
€ 2,32
Turnover (x 1 mln)
€ 27,52
€ 27,61
€ 30,57
€ 36,84
€ 41,85
Price year-end
€ 2,35
€ 1,49
€ 1,73
€ 2,30
€ 4,18
Year high
€ 3,94
€ 1,89
€ 2,44
€ 4,84
€ 5,67
Year low
€ 1,34
€ 1,48
€ 1,17
€ 2,17
€ 3,72
Outstanding shares (x 1 mln)
10,031
9,729
9,729
9,676
9,639
Price to Earnings
-3,339
-2,895
-4,795
-1,301
17,367
Earnings per share
€ -0,70
€ -0,51
€ -0,36
€ -1,77
€ 0,24
Dividends
-
-
-
-
€ 0,08
Dividend yield
-
-
-
-
1,91%
Pay out
-
-
-
-
33,24%
Private equity (x 1 mln)
€ 15,25
€ 21,29
€ 26,77
€ 29,83
€ 47,22
PE per share
€ 1,52
€ 2,19
€ 2,75
€ 3,08
€ 4,90
Balance total (x 1 mln)
€ 48,14
€ 46,88
€ 51,46
€ 55,62
€ 72,41
Stockmarket value (x 1 mln)
€ 23,57
€ 14,51
€ 16,83
€ 22,25
€ 40,29

Company analysis

 

Analysis of profit indicators

Average profit per share (4 years)
€ -0,78
Standard deviation average profit
€ 0,75 (-96,86%)
Average annual growth rate
-74,82%
Compound annual growth percentage
-30,77%